| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
Clinical Trials Recruiting - September 26th, 2006Alzheimer DiseaseAntigonadotropin - Leuprolide in Alzheimer's Disease Drug Investigation (ALADDIN) - is a clinical trial investigating the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's Disease (AD). The study seeks men 65 years and older with mild to moderate Alzheimer's disease. Visit http://www.clinicaltrials.gov then enter ALADDIN in the search request box to view locations of recruiting sites or to learn more about the study. Margolin Brain Institute - Patients at least 45 years old with mild memory loss, may qualify to participate in a clinical research trial of an investigational medication. All study related evaluations and study medication are provided at no cost and there is a travel allowance. Contact the Margolin Brain Institute 559-299-1515. Patients who have memory loss as a result of a stroke, may be eligible to participate in a medical research study. Participants will receive study related evaluations and medications at no cost, which may include: CT or MRI Scan, ECG, Lab Tests, Memory Testing, Physical Exam, or Study Medication. For more information, Contact the Margolin Brain Institute 559-299-1515. Patients with mild-to-moderate Alzheimer's disease may qualify to receive an investigational Alzheimer's medication. Patients may continue taking prescription Alzheimer's medication. Qualified applicants receive travel reimbursement. Contact the Margolin Brain Institute 559-299-1515. Patients with mild-to-moderate dementia may qualify to participate in a clinical research study of an investigational medication. Study medications and all assessments are provided at no cost, and up to $520.00 in travel reimbursement. Contact the Margolin Brain Institute 559-299-1515. Memory & Aging Program, Butler Hospital - Patients 55 and older with mild Alzheimer’s disease may qualify to participate in a Phase III trial of Flurizan, a selective amyloid lowering agent that reduces toxic amyloid in cultured human cells and animal models. Contact the Memory & Aging Program at 401-455-6402 or e-mail MHinckley@Butler.org Patients between the ages of 50 – 85 with mild to moderate Alzheimer’s disease may qualify to participate in a beta amyloid active immunotherapy study designed to induce highly specific antibodies to bind and clear amyloid peptide. For additional information, contact the Memory & Aging Program at 401-455-6402 or e-mail MBowker@Butler.org Patients 65 and older with mild to moderate Alzheimer’s disease may qualify to participate in a 13-month, Phase III trial of an investigational medication that may inhibit cell cycling and slow the progression of Alzheimer’s disease. Contact the Memory & Aging Program at 401-455-6402 or e-mail MBowker@Butler.org Myriad Pharmaceuticals is evaluating the efficacy and safety of MPC-7869 (Flurizan, R-flurbiprofen), an investigational agent with an amyloid lowering mechanism. The study seeks patients with mild Alzheimer’s disease aged 55 or older, with a caregiver, and living in the community. Visit www.myriadtrials.com for information on this clinical research study or call 1-800-649-7316 for information. National Institute on Aging: Antioxidant Treatment: A 5-month study seeking participants with mild to moderate Alzheimer’s disease. The study will examine the safety and effectiveness of two anti-oxidant treatment regimens with lumbar puncture, and venipuncture. Sponsored by the National Institute on Aging (NIA). Visit http://www.clinicaltrials.gov 6-month study seeking participants 55 and older, with mild to moderate Alzheimer’s disease to evaluate Chinese herb huperzine A in treatment of Alzheimer's disease. Participants can receive huperzine at no cost for an additional 6 months. Sponsored by the National Institute on Aging (NIA). Visit http://www.clinicaltrials.gov Valproate Neuroprotection: A 26-month study seeking participants age 55 or older who have been diagnosed with Alzheimer’s disease, to determine whether valproate therapy delays the emergence of agitation and/or psychosis in patients. Sponsored by the National Institute on Aging (NIA). For more information, visit http://www.clinicaltrials.gov National Institute of Mental Health- The Depression in Alzheimer’s Disease Study II is a 24-week clinical trial to determine the effect of an anti-depressant medication (Zoloft) on the cognitive functioning and mood of people with Alzheimer’s disease and depression conducted at (MD, PENN, CA, NY, SC). Visit www.priresearch.com New York School of Medicine - This NYU School of Medicine study will determine whether individualized care can further slow the progression of Alzheimer’s in patients given memantine. Individualized care involves getting the patient exercising, doing enjoyable activities and cognitive stimulation, as well as providing support and training for caregivers. Call: Sunnie Kenowsky at 212-263-7164. UCLA Kagan Alzheimer's Disease Research Center - Curcumin study. The curcumin study is a 12 month, phase II, UCLA initiated drug trial, with the first 6 months being randomized, placebo controlled, and the second 6 months being open label. This study will be investigating the safety and effectiveness of curcumin, a natural dietary component, with the antioxidant, anti-inflammatory and cholesterol lowering properties, to slow the progression on Alzheimer's disease. For more information, call 310-206-3779. The University of Washington, Seattle seeks volunteers with mild to moderate Alzheimer’s Disease (AD), living at home, to participate in a placebo controlled trial of a gamma secretase inhibitor, that may reduce levels of amyloid in the Cerebrospinal fluid (CSF). This is a 29-week study, participants may remain on standard AD medications. 800-317-5382. The University of Washington, Seattle seeks volunteers with mild to moderate AD to take part in a study with an experimental drug. It is hoped that the study drug will attach to amyloid protein in the brain and help the body to remove it. Some people will receive a placebo. All study visits are at the Seattle Veteran's Hospital. For more information, please contact 800-317-5382. University of Wisconsin: Soy's Potential Effects on Cognition in the Treatment of Alzheimer's (SPECTRA) conducted by the Wisconsin Comprehensive Memory Program, affiliated with the University of Wisconsin-Madison and the Madison VA Medical Center: The purpose of this research study is to evaluate the potential effects of soy isoflavone supplements compared to placebo (a pill with no active medicine), on cognitive function for men and women with Alzheimer's Disease (AD). If you are interested, please visit our website for more information http://memoryresearch.medicine.wisc.edu University of Wisconsin: Therapeutic Potential of Estrogen. The University of Wisconsin-Madison, and the Madison VA Medical Center are looking at whether treatment with estrogen will result in better day-to-day functioning for persons with Alzheimer's disease. For more information, visit our website: http://memoryresearch.medicine.wisc.edu The UW Alzheimer's Disease Research Center is enrolling persons with Alzheimer's disease (AD) in a study to see if a combination of dietary antioxidant supplements or a single antioxidant is safe to take and to investigate possible side effects. This study may help researchers learn more about antioxidants as a treatment for AD. One out of every three participants will receive placebo, a pill that does not have any active medication in it. All study visits take place at the Seattle Veterans Hospital. For more information, please call 800-317-5382 or 206-764-2069. Back to Medical Conditions list.
Amyotrophic Lateral SclerosisBeth Israel Deaconess Medical Center, Boston is seeking adults with ALS for a research study evaluating whether breath training can improve respiratory function and quality of life. The study involves 8 visits over 6 months. Subjects must have a forced vital capacity (FVC) of 50%-80% predicted. Study procedures are provided at no cost to participants. For further information, contact Kristi Hembre at 617-667-3098 or ALSdiaphragm@bidmc.harvard.edu Columbia University – The ALS Association-supported Phase II Combination Drug Selection Trial in ALS is seeking patients, 21-85 years of age, with ALS onset < 5 years, and FVC > 60%. The trial tests combinations of minocycline/creatine and celecoxib/creatine, and has 20 participating sites across the US. For more information, please contact Carolyn Doorish at cd2141@columbia.edu Mount Sinai School of Medicine—The MDA/ALS Program at Mount Sinai School of Medicine is evaluating the safety and efficacy of an investigational medication for its ability to lower SOD1 levels in patients with the SOD1 form of Familial Amyotrophic Lateral Sclerosis (FALS). For more information, visit www.mssm.edu/neurology/neuromuscular/als/clinical_trials.shtml email: gregory.seidel@mssm.edu or call 212-241-8389. Back to Medical Conditions list.
Attention Deficit DisorderThe Strong Neurology Attention Deficit Hyperactivity Disorder (ADHD) clinic at the University of Rochester Medical Center is currently conducting a research study January (1 of 2) 2006 NEUROLOGY 66 75A using two medications (Clonidine and Methylphenidate) for children 4-6 years of age who have or may have ADHD. This study is looking to assess the affects of these two medications used in combination to treat ADHD. Participants in the study will receive an evaluation by specialists in diagnosing and treating ADHD. Children who qualify may be eligible for a free research study. For more information, please call Melissa at 585-341-7516. Back to Medical Conditions list.
AutismThe Vanderbilt Kennedy Center is recruiting families of children with and without autism to participate in a study of the relationship between sleep patterns and behavior in children with autism. Children between the ages of 4 and 10 years, are seizure free and are currently not on psychotropic medications are needed. For further information, please contact: Karen Adkins, RN, MA, CCRC at 615-936-1646 or by e-mail Karen.Adkins@Vanderbilt.edu Back to Medical Conditions list.
CADASILButler Hospital/Brown Medical School (Providence, Rhode Island) is conducting an 18 week double-blind study of a cholinesterase inhibitor to treat cognitive impairment in patients with CADASIL. For further information about the study, please contact Stephen P. Salloway, MD, Butler Hospital, 345 Blackstone Boulevard, Providence, Rhode Island 401-455-6402. Back to Medical Conditions list.
Cerebral PalsyDayton, Ohio Children’s Medical Center/Wright State University- Children ages 3-8 years with spastic cerebral palsy are being recruited for a blinded research study examining the effects of hyperbaric oxygen vs. hyperbaric air. Testing will be done just prior to treatment (40 dives), immediately and six-months after treatment is finished. Study procedures and testing are being provided at no cost to participants. For more information, please contact: Connie Bruns, RN at 937-641-4279; E-mail:BrunsC@childrensdayton.org National Institutes of Health (NIH), Bethesda seeks people ages 6-30 with hemiplegic or diplegic cerebral palsy for a study (Protocol 04-N-0098) and of brain reorganization at the NIH. The study involves 3 outpatient visits. Study procedures and evaluations of rehabilitation needs are provided at no cost to participants. This study is carried out in compliance with testing and safety standards of U.S. Department of Health and Human Services. Contact us toll free at 800-411-1222; TTY: 866-411-1010; e-mail: prpl@cc.nih.gov Back to Medical Conditions list.
Cervical DystoniaNIH Clinical Center, Bethesda is seeking adults with cervical dystonia receiving botulinum toxin, but no other dystonia medications for a research study evaluating whether amlodipine can enhance toxin efficacy. Patients must be otherwise healthy and without hypertension. This outpatient study involves 10 visits over 9 months to the NIH Clinical Center, Bethesda, MD There is no cost to study participants and travel and lodging will be provided by NINDS. Contact Barbara I. Karp, MD at 301-496-0510 or e-mail karpb@ninds.nih.gov This study is carried out in compliance with testing and safety standards of the U.S. Department of Health and Human Services. Back to Medical Conditions list.
Chronic FatigueNew Jersey Medical School - We are seeking 30-50 y/o women with medically unexplained fatigue producing substantial decreases in activity to participate in a study of immune function during sleep. Participants are evaluated at no cost and are reimbursed for their time and local travel expenses. For more information see www.umdnj.edu/cfs or call (973) 395-7900. Back to Medical Conditions list.
DementiaNational Institutes of Health (NIH), Bethesda - Persons with Frontotemporal Dementia or Pick's disease, aged 21-80, are needed for a study involving neuropsychological and genetics testing, MRI and PET scans at the NIH, (Protocol 81-N-0010). Study involves 1 to 2 weeks inpatient or outpatient stay at NIH at no cost to participant. Travel provided for the participant and caregiver. This study is carried out in compliance with testing and safety standards of the U.S. Department of Health and Human Services. Contact Jordan Grafman, PhD at 301-496-0220 or grafmanj@ninds.nih.gov Back to Medical Conditions list.
DepressionNIMH-supported research study of major depression associated with delusions:A four-site collaborative, randomized, double-blind, controlled trial comparing olanzapine plus placebo to olanzapine plus sertraline. Medical Schools of the Universities of Pittsburgh, Toronto, Massachusetts in Worcester and Weill Cornell in Westchester, NY. Phone Judith English at Cornell: 914-997 8636. Back to Medical Conditions list.
DysphagiaNational Institutes of Health (NIH), Bethesda - Adults with dysphagia of more than six months are needed for a study of electrical stimulation to prevent aspiration. The study requires a3-day NIH inpatient admission of the participant. There are no costs to participants or companions. The studies will be carried out under testing and safety standards of the Department of Health and Human Services at the National Institutes of Health. Contact Christy Ludlow at 301-496-9367, 10 Center Drive, MSC 1416 Building 10, Room 5D38, Bethesda, MD 20892-1416; e-mail ludlowc@ninds.nih.gov Back to Medical Conditions list.
EpilepsyJohnson & Johnson Pharmaceutical Research & Development, L.L.C. seeks patients for 2 randomized clinical research trials in pediatric epilepsy. The trials will evaluate the investigational use of a marketed antiepileptic drug (topiramate) for the adjunctive treatment of partial-onset seizures in subjects younger than 2 years. More information at: http://clinicaltrials.gov/ct/show/NCT00113815?order=1> and http://clinicaltrials.gov/ct/show/NCT00233012?order=1>> National Institute of Health (NIH) in Bethesda is seeking people five and older with seizures for in- and outpatient research studies at the NIH including TMS, MEG, PET and MRI Scans. Screening will determine eligibility for particular protocols. All study-related expenses will be paid by the NIH. For more information, contact Dr. William Theodore 301-496-1505. This study is carried out in compliance with testing and safety standards of the U.S. Department of Health and Human Services. National Institutes of Health (NIH)- People five and older with seizures are sought for in- and outpatient research studies at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, including Transcranial Magnetic Stimulation, Magnetoencephalography, PET and MRI scans. Screening will determine eligibility for particular protocols. All study-related expenses will be paid by the NIH. For more information contact Dr. William Theodore, 301-496-1505. The studies are carried out in compliance with testing and safety standards of U.S. Department of Health and Human Services. National Institutes of Health (NIH)- Medically intractable epilepsy patients 18-70 years old sought for inpatient study of convective delivery of muscimol to seizure focus. Purpose is to develop brain infusion therapy for this condition. Standard surgical treatment provided after infusion. Study-related expenses paid by NIH. More information at http://clinicaltrials.gov/ct/show/NCT00005925?order=1> or contact Dr. John Heiss, 301-496-2921. Rhode Island Hospital/Brown Medical School is conducting a 12 week pilot, randomized, placebo-controlled, double-blind trial, of an SSRI for comorbid symptoms in nonepileptic seizures (NES). For information about the study, please contact W. Curt LaFrance, Jr., MD, RIH, Potter 3 Neuropsychiatry, 593 Eddy Street, Providence, Rhode Island, 02903, 401-444-3534, William_LaFrance_Jr@Brown.edu University of Arizona Department of Neurology is seeking patients who have experienced at least 2 partial seizures in the last 6 months and are currently treated with carbamazepine or phenytoin. This study is investigating the behavioral effects of Lamictal and Keppra in the treatment of epilepsy. For more information, call 520-626-0868. Back to Medical Conditions list.
HeadacheDynamic Health Resources— Research is being conducted by Dynamic Health Resources to evaluate a nutritional alternative using a nutritional supplement SerotonaTM (Neurobiology Formula 12397) and migraine trigger elimination diet with the goal of reducing the frequency, duration and intensity of migraine pain. This national study is recruiting migraine suffers between the ages of 18 to 72, experience one or more migraines each month, and are not getting enough relief from over the-counter or drug medications. For more information call 757-962-7081; E-mail: Katherine@DynamicHealthResoureces.com or visit www.MigrainePreventionStudy.com Michigan Head-Pain and Neurological Institute is seeking volunteers to participate in evaluating the benefit of PFO closure in patients with migraine headaches and PFO. The goal to determine if using an investigational device to close the PFO will improve migraines. Study related testing/ procedures provided. For more information, contact: Dr. Joel Saper 734-677-6000, X4. Back to Medical Conditions list.
Huntington DiseaseMinocycline in Huntington's Disease (DOMINO)— This study, funded by the Orphan Products Division of September (2 of 2) 2006 NEUROLOGY 67 67A the FDA, will assess the safety and tolerability of minocycline in 100 subjects, age 18 or older with manifest HD. Subjects will be followed approximately every three months for 18 months. Visit http://www.huntington-study-group.org for the locations of recruiting sites. The University of Iowa, NINDS PREDICT-HD (Neurological Predictors of Huntington's disease) is studying early biomarkers in people who have had the genetic test for Huntington's Disease, but have no symptoms. Results will inform clinical trials for Huntington's disease. Participation is available at 25 research sites: Elizabeth Penziner 319-353-4292 or elizabeth-penziner@uiowa.edu Back to Medical Conditions list.
Lennox-Gastaut SyndromeOvation Pharmaceuticals seeks patients with Lennox-Gastaut Syndrome for a randomized study evaluating the safety and efficacy of clobazam as an adjunctive therapy. Inclusion is for ages 2 to 30 years who have greater than 1 type of generalized seizures, including drop seizures. More information may be found at: http://clinicaltrials.gov/ct/show/NCT00162981?order=64 Back to Medical Conditions list.
Mild Cognitive ImpairmentNational Institute of Aging: Alzheimer's Disease Neuroimaging Initiative: 5 year study seeking participants with and without memory problems, age 55 through 90. Study will examine how brain imaging technology can be used with other tests measuring progression of mild cognitive impairment and early Alzheimer’s disease. Sponsored by the NIA, NIBIB, ISOA, and AA. Visit http://clinicaltrials.gov Back to Medical Conditions list.
Multiple SclerosisThe BEYOND Study: This international trial sponsored by BERLEX investigates the efficacy and safety of two doses of Betaseron® (500 mcg and the approved dose of 250 mcg) and also compares Betaseron® against Copaxone®. This study is currently enrolling treatmentnaïve patients with relapsing-remitting MS, who are between the ages of 18 and 55 years, have experienced at least one relapse within the past 12 months, and are able to walk at least 200 meters without aid or rest. For more information please call 800-788-1467 or visit www.clinicaltrials.gov/show/NCT00099502 MSBasis Study: is seeking MS Neurologists worldwide to register their site and participate in an observational study of patients with CIS or early MS (diagnosed 12 months ago). This investigator driven 5-year study aims to observe routine clinical care and measure key MS related outcomes in the long term. For information please contact study site on msbasis@mh.org.au National Institutes of Health - A multi-center, NIHNINDS supported clinical trial examining the combined use of interferon beta 1-a weekly and glatiramer acetate daily as initial treatment for patients with relapsingremitting multiple sclerosis. The purpose of the study is to determine if the combined use of these agents will help reduce relapse rate when compared to either agent alone. This study is enrolling men and women between the ages of 18 to 60 across the U.S. and Canada who have RRMS, have experienced at least two relapses in the previous 3 years and have never received treatment with a disease-modifying agent. All eligible participants will receive at least one active agent. To find a participating study center or site in your area or more information please call 866-848-3088 or e-mail: combirx@mssm.edu National Institutes of Health - An important companion study to CombiRx, the NIH-NINDS sponsored Biomarkers in MS project will examine a variety of biological markers at baseline and additional points during the study. These data, in conjunction with clinical and MRI data, should provide a means for identifying, in the future, those patients with more aggressive disease as well as patients who respond or fail to respond to single or combination drug treatment. Such markers would have considerable value in the management of patients as well as potentially leading to new approaches to therapy. For eligibility requirements, please refer to the CombiRx listing. To find a participating study in your area or more information please call 866-848-3088 or e-mail: combirx@mssm.edu Yale University School of Medicine (PI:Dr.Jana Preiningerova,MD,HIC #0507000406)is currently enrolling subjects for a double blind placebo controlled clinical trial of BOTOX (Botulinum toxin A) for legs spasticity in patients with Multiple sclerosis with focus on improvement of function over 3 months. For more information contact Sarah Harma at 203-764-8160 or e-mail sarah.harma@yale.edu Back to Medical Conditions list.
Multiple System AtrophyThe North American Multiple System AtrophyStudy Group is seeking patients with multiple systematrophy for a research study to identify environmentaland genetic factors associated with the disorder.Subjects will be provided with a physical examination,and be asked to provide a blood sample for DNA testing.Interviews will also be done by telephone as part of thisstudy. This study is sponsored by the National Institutesof Health (NIH). Subjects can be seen at 11 medical cen-ters in the United States. For more information pleasecontact Deborah Fontaine at 858-622-5800. Back to Medical Conditions list.
Muscular DystrophyUniversity of Iowa Department of Pediatric Neurology is seeking patients of all ages with fukutinrelated protein genetic mutations resulting in limb girdle muscular dystrophy type 2I (LGMD 2I) or congenital muscular dystrophy type 1C (MDC 1C) for a clinical study defining phenotype and determining reasons for differences in disease severity. Participation involves surveys and yearly clinical evaluations. Reimbursement for travel is available. For more information call: Carrie Stephan at 319-356-2673. Back to Medical Conditions list.
NeurogeneticsBeth Israel Deaconess Medical Center in Boston: Brain Malformation Study. Dr. Christopher Walsh's neurogenetics laboratory at Beth Israel Deaconess Medical Center in Boston is enrolling families for research to identify genes associated with brain malformation disorders including lissencephaly, microcephaly, polymicrogyria, pachygyria and Walker-Warburg Syndrome. For information contact research coordinators Adria Bodell or Kira Apse at walshlab@bidmc.harvard.edu Back to Medical Conditions list.
PainBrigham and Women's Hospital Department of Anesthesiology - is conducting a research project to evaluate investigational drugs as a treatment for specific types of pain caused by spinal cord injury (SCI). Individuals between the ages of 18 and 70 with SCI who have had persistent pain for a minimum of three months following SCI may be eligible. The study requires 5 or 6 hospital visits over the course of 31 weeks. Please contact Kate Jenkins at 617-525-PAIN (7246), or e-mail: mailto:paintrials@partners.org Diabetic Peripheral Neuropathy - We are enrolling 200 subjects in a multicenter, randomized, placebo-controlled trial who have moderate/severe neuropathic pain from DPN. This is a three-month study with 2 hours stimulation/day. Selective sites will also utilize serial punch biopsy (ENF) and autonomic testing to determine objectively if there is nerve regeneration or improved function. For more information call: Michael I. Weintraub, MD, FACP, FAAN, Principal Investigator, 914-941-0788; Fax: 914-941-0562. MyoLink, LLC David R Hubbard, MD is sponsoring an IRB-approved, FDA double-blind, placebo-controlled trial of MyoX™ (phenoxybenzamine formulated for intramuscular use) injected into trigger points under needle EMG guidance. Four investigator sites: Bethesda MD, Charlotte NC, Sunrise FL, and La Jolla CA are recruiting up to 100 subjects. For more information please visit www.trigger-point-injections.com Back to Medical Conditions list.
Parkinson DiseaseCleveland Clinic Foundation, Center for Neurological Restoration, (PI: Jerrold Vitek, M.D., Ph.D.) is currently enrolling subjects ages 30-75 for Deep Brain Stimulation for the Treatment of Advanced Parkinson’s Disease. For more information please contact: study coordinator Terese Wheeler at wheelet@ccf.org Colorado Neurology, P.C. (PI: Pinky Agarwal,MD) is recruiting patients for a research study with advanced Parkinson's disease who have motor fluctuations. Patients must be taking maximum dose of a dopamnine agonist with carbidopa/levodopa- Patients will receive high dose Requip® For more information please call 303-788-4600. Johns Hopkins University (PI: Laura Marsh, MD) is currently enrolling subjects over 50 years old for a Doubleblind placebo-controlled trial of memantine for treatment of cognitive impairment in patients with Parkinson's disease and dementia. The study lasts approximately 6 months. For more information contact Melissa Gerstenhaber R.N. at 410-614-1242 or e-mail at mgerste1@jhmi.edu The Experimental Therapeutics Branch, NINDS, is recruiting patients with Parkinson's disease (age 30-80), for a placebo-controlled study evaluating the use of transcutaneous lisuride in the treatment of levodopa-induced motor complications. The study lasts approximately 4 months and involves three shortinpatient admissions to the Clinical Center of the National Institutes of Health, Bethesda, MD. There is no cost to participants, including travel to NIH. Contact Tzvetelina Dimitrova, M.D., at 301-496-4604 or DimitroT@ninds.nih.gov This study is carried out in compliance with testing and safety standards of U.S. Department of Health and Human Services. Margolin Brain Institute - Parkinson's patients taking Carbidopa/Levodopa and having fluctuations in their motor function, may qualify to participate in a research study and receive an investigational medication that may help to reduce motor fluctuations. The investigational medication and study related health care are provided at no cost for this clinical research trial. Qualified participants will receive travel reimbursement up to $175.00. Contact: the Margolin Brain Institute 559-299-1515. Memory & Aging Program, Butler Hospital—Brown Medical School: Study of investigational medication beta amyloid immunotherapy with a monoclonal antibody designed to bind and clear beta amyloid peptide. Phase II placebo controlled trial for patients ages 50 – 85 with mild to moderate Alzheimer’s disease. Contact: Donna Cimini, RN at 401-455-6402 or e-mail:dmcimini@butler.org Ovation Pharmaceuticals is currently looking for patients with a diagnosis of psychosis associated with Parkinson’s disease who may be eligible for participation in a multi-center, randomized, double-blind, placebocontrolled study exploring the safety and effectiveness of melperone (an atypical antipsychotic). Contact: Deborah Kniuskta at kniuksta.deborahl@kendle.com for information about site locations. Parkinson's Research: The Organized Genetics Initiative is an NIH sponsored study recruiting brothers and sisters with PD. The study is attempting to identify genetic components of PD. Subjects will undergo a clinical examination and provide a blood sample for DNA extraction. Please call 888-830-6299 for more information. Study of Antidepressants in Parkinson's Disease (SAD-PD), an NIH-funded, double-blind, placebo-controlled, multicenter (15 sites, 228 subjects) clinical trial, will evaluate the efficacy and tolerability of antidepressants paroxetine and venlafaxine in PD patients with depression. Contact: Nancy Pearson (Project coordinator, University of Rochester) at 585-273-2982 or search "SAD PD" at www.clinicaltrials.gov University of California San Francisco is seeking adults between the ages of 40 to 75 yrs of age with midto late- stage Parkinson’s disease to participate in a Phase I research trial to evaluate the safety of a gene transfer product. The study will involve a neurosurgical procedure similar to deep brain stimulation, but in which the gene transfer products will be delivered to targeted areas in the brain to locally increase the production of dopamine. Please call 415.476.4097 for more information. Back to Medical Conditions list.
Peripheral NeuropathyAvanir Pharmaceuticals is seeking subjects 18-80 years with diabetes who have distal symmetrical painful diabetic neuropathy, a common complication of diabetes, to participate in a research study to test the safety of an investigational medication known as AAVP-923 (NMDA receptor antagonist). To learn more, go to www.clinicaltrials.gov National Institute of Health is funding a gene therapy study to evaluate intramuscular gene transfer using VEGF (Vascular Endothelial Growth Factor) in patients with diabetic neuropathy in the legs. This condition causes a decrease in feeling and sensation due to diabetes. Work-up is required and enrolled participants will be followed for approximately one year. There are two sites for this study. Caritas St. Elizabeth's Medical Center, Boston, MA: Principal Investigator: Allan Ropper, MD. Contact: Jacquelyn E. Briggs 617-779-6394. Columbia University Neuropathy Research Center, Neurological Institute, New York, NY: Principal Investigator: Clifton Gooch, MD. Contact: Lyn Goldsmith 212-305-6035. To learn more, go to www.clinicaltrials.gov NCT00056290. Back to Medical Conditions list.
Progressive Multifocal Leukoencephalopathy (PML)Beth Israel Deaconess Medical Center (Boston,MA) - The HIV/Neurology Center is conducting aresearch project to evaluate the immunological, virologi-cal and radiological prognostic factors of disease evolu-tion in PML. Individuals diagnosed with PML will be evaluated over a period of one year. Please contact: Dr Igor Koralnik at 617-667-1568 or ikoralni@bidmc.harvard.edu Back to Medical Conditions list.
Progressive Supranuclear PalsyThe University of Louisville Movement Disorder Program, Kentucky is seeking patients with progressive supranuclear palsy for a multi-center study toidentify environmental and genetic risk factors associated with the disease. Subjects will be provided with a physical and neuropsychological examination, will be asked to provide a blood sample for DNA testing and will take part in a detailed phone interview. This study is sponsored by the National Institutes of Health (NIH). Subjects can be seen at 8 medical centers throughout the United States. For more information please call 1-866-PSP-0448 (1-866-777-0448). Back to Medical Conditions list.
Restless Legs SyndromeJohns Hopkins - Individuals with Restless Legs Syndrome are needed for a research study at Johns Hopkins. This is a randomized, double-blind, placebo controlled study using 1000mg infusion of iron Venofer® for RLS symptoms. All travel will be provided. For more information, please contact Jim at 410-550-2252 or jstone8@jhmi.edu PI: Dr. Earley #HBV00-05-12-01 Back to Medical Conditions list.
Spinal Muscular AtrophyStanford University is investigating safety and efficacy of hydroxyurea treatment and is seeking SMA patients with homozygous SMN gene deletion. Type I patients must be younger than 2 years and diagnosed within the last 6 months. Type II or III patients must be between 16 months and 10 years of age. Call Tony Trela at 650-498-7658, e-mail sma@stanfordmed.org or visit http://sma.stanford.edu/ for more information. Spinal Muscular Atrophy (SMA) Project Cure SMA (PCSMA) is seeking patients, ages 2-12, who have been genetically diagnosed with SMA. At time of enrollment, they can have no significant contractures, spinal fusions, or be on ventilation of any type. Contact PCSMA (800) 886-1762 or http://www.curesma.com/ Spinal Muscular Atrophy (SMA) Project Cure SMA (PCSMA) is seeking patients under age 2 who have been genetically diagnosed with SMA. At time of enrollment they can have no significant contractures, spinal fusions, or be on ventilation of any type. Contact PCSMA (800) 886-1762 or http://www.curesma.com/ Back to Medical Conditions list.
StrokeThe Albumin in Acute Stroke (ALIAS) Trialis enrolling subjects with acute ischemic stroke in an NIH-funded multicenter randomized clinical trial to determine whether treatment with high-dose human albumin within 5 hours of stroke onset confers neuroprotection; primary outcome measures are NIH Stroke Scale and modified Rankin Scale at 3 months. 45 U.S. and Canadian sites are participating. Contact: Dr. Myron D. Ginsberg, 305 243-6103, mdginsberg@stroke.med.miami.edu Carotid Occlusion Surgery Study (COSS) is enrolling subjects in a multi-center randomized clinical trial to determine if extracranial-intracranial bypass surgery can reduce subsequent ipsilateral ischemic stroke in subjects with recently symptomatic carotid artery occlusion and ipsilateral increased oxygen extraction fraction. Information: www.cosstrial.org at Washington University School of Medicine. Funded by NIH/NINDS. Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), NIH Grant #RO1 NS038384 -compares carotid artery stenting (CAS) to carotid endarterectomy (CEA) for the treatment of stenosis to prevent recurrent strokes in those who have had a TIA or a mild stroke within the past 6 months (symptomatic) and in those who have not had any symptoms within the past 6 months (asymptomatic). Major inclusion criteria: symptomatic subjects with recent neurological events with carotid stenosis greater than 50% by angiography or 70% by ultrasound; asymptomatic subjects with no recent neurological events referable to the study artery and carotid stenosis greater than 60% by angiography or greater than 70% by ultrasound are eligible for randomization. Participants will be followed for up to four years. Participants must be over the age of 18. For more information, please call Mary Hampton at 904-953-7742 or visithttp://www.cresttrial.org/ The CI Therapy Research Group of the University of Alabama at Birmingham - is recruiting adult patients with chronic stroke (>1yr) for a NIH-supported trial to determine the efficacy of components of CI therapy for patients with mild/moderate motor symptoms. The therapy involves intensive training of the more affected arm for 10 consecutive weekdays while wearing a mitt on the less affected arm for a target of 90% of waking hours. Contact person: Adriana Delgado, 205-934-9768, adelgado@uab.edu The Insulin Resistance Intervention after Stroke (IRIS) Trial is seeking patients with a recent ischemic stroke for a study of pioglitazone (a medication that improves insulin resistance) compared with placebo for prevention of recurrent stroke and myocardial infarction. Eligible candidates are non-diabetic, over age 44-years and insulin resistant according to a fasting blood test that will be performed by the investigators. Contact Dr. Walter Kernan at 866-274-5729 or visit our website http://iristrial.org/Funded by the National Institutes of Health. National Institute of Health (NIH), Bethesda seeks adults who have had a stroke within the past 6 months for a functional magnetic resonance imaging (fMRI) study (Protocol 03-N-0049) involving repetitive transcranial magnetic stimulation (rTMS) and pinch grasp at the NIH. This study involves 1 or 2 outpatient visits at no cost to the participant. Travel and lodging are provided for the participant and caregiver. This study is carried out in compliance with testing and safety standards of U.S. Department of Health and Human Services. Contact Deog Young Kim, MD, PhD at (301) 402-3493 or kimdy@ninds.nih.gov Siblings with Ischemic Stroke Study (SWISS) is an NIH-sponsored sibling pair study of genetic risk factors. SWISS is looking for participants with symptomatic ischemic stroke and at least one living sibling with a stroke. Please have potentially eligible patients contact Mayo Alliance for Clinical Trials at 800-541-5818 for more information. Back to Medical Conditions list.
TremorColorado Neurology, P.C. (PI: Pinky Agarwal,MD) is recruiting patients for a clinical research study evaluating the safety and effectiveness of Botulinum Toxin Type A in patients with essential head tremor. Patient must not have received botulinum toxin within 4 moths of enrollment. For more information call 303-783 4976. Back to Medical Conditions list.
|